Coumaran Égile

5.2k total citations
52 papers, 4.0k citations indexed

About

Coumaran Égile is a scholar working on Molecular Biology, Cell Biology and Genetics. According to data from OpenAlex, Coumaran Égile has authored 52 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 15 papers in Cell Biology and 13 papers in Genetics. Recurrent topics in Coumaran Égile's work include Cellular Mechanics and Interactions (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). Coumaran Égile is often cited by papers focused on Cellular Mechanics and Interactions (15 papers), Chronic Lymphocytic Leukemia Research (12 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). Coumaran Égile collaborates with scholars based in France, United States and Spain. Coumaran Égile's co-authors include Philippe Sansonetti, Dominique Pantaloni, Rong Li, Marie-France Carlier, Dominique Didry, Christophe Le Clainche, Rong Li, Valérie Laurent, Stéphane Romero and Thomas P. Loisel and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Coumaran Égile

51 papers receiving 4.0k citations

Peers

Countries citing papers authored by Coumaran Égile

Since Specialization

Citations

This map shows the geographic impact of Coumaran Égile's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coumaran Égile with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coumaran Égile more than expected).

Fields of papers citing papers by Coumaran Égile

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Coumaran Égile. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coumaran Égile. The network helps show where Coumaran Égile may publish in the future.

Co-authorship network of co-authors of Coumaran Égile

This figure shows the co-authorship network connecting the top 25 collaborators of Coumaran Égile. A scholar is included among the top collaborators of Coumaran Égile based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coumaran Égile. Coumaran Égile is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing 2023 ·Genes Chromosomes and Cancer ·Melanie A. Jones, Kirsten M. Timms, (unknown), Elizabeth S. Cogan, (unknown), M. D. Perry, Brian Morris, (unknown), Cathy E. Elks, Pierre Lao‐Sirieix, Simon Dearden, Coumaran Égile, Jessica Brown, Elizabeth A. Harrington, Darren Hodgson, (unknown), Thomas P. Slavin, Debora Mancini‐DiNardo	3
2	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer 2020 ·Investigational New Drugs ·Jin‐Ji Yang, Jian Fang, Yongqian Shu, Jianhua Chang, Gongyan Chen, (unknown), Wěi Li, Xiaoqing Liu, Nong Yang, Caicun Zhou, Jian Huang, Melanie M. Frigault, Ryan J. Hartmaier, (unknown), Coumaran Égile, Shethah Morgan, Remy B. Verheijen, Anders Mellemgaard, Liu Yang, Yi‐Long Wu	43
3	Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma 2015 ·Clinical Cancer Research ·Jennifer R. Brown, Matthew S. Davids, Jordi Rodón, Pau Abrisqueta, Siddha Kasar, Joanne Lager, Jason Jiang, Coumaran Égile, Farrukh T. Awan	45
4	The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells 2015 ·Leukemia ·Rachel Thijssen, (unknown), (unknown), Martin F. M. de Rooij, Annemieke Kuil, (unknown), Taco W. Kuijpers, Joke W. Baars, Angéla Virone-Oddos, Marcel Spaargaren, Coumaran Égile, Marinus H. J. van Oers, Eric Eldering, Marie José Kersten, Arnon P. Kater	20
5	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Égile, Rodrigo Ruiz-Soto, Alexander Laird, Dale Miles, Patricia LoRusso	87
6	The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET -Amplified Cancer 2014 ·Molecular Cancer Therapeutics ·Coumaran Égile, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jean‐Paul Nicolas, (unknown), (unknown), Elisa Francesconi, (unknown), Anne‐Marie Lefebvre, Conception Nemecek, Loreley Calvet, Hélène Goulaouic	23
7	MET Genetic Abnormalities Unreliable for Patient Selection for Therapeutic Intervention in Oropharyngeal Squamous Cell Carcinoma 2014 ·PLoS ONE ·Ludovic Lacroix, (unknown), Alexander Valent, Antoine E. Melkane, Philippe Vielh, Coumaran Égile, (unknown), (unknown), Sandrine Micallef, Patrick Saulnier, Hélène Goulaouic, Anne‐Marie Lefebvre, Stéphane Temam	14
8	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma 2014 ·Gynecologic Oncology ·Ursula A. Matulonis, Ignace Vergote, Floor Backes, Lainie P. Martin, Scott McMeekin, Michael J. Birrer, Frank Campana, Yi Xu, Coumaran Égile, Sharad Ghamande	88
9	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, Alexander Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman	123
10	Three‐dimensional reconstructions of Arp2/3 complex with bound nucleation promoting factors 2011 ·The EMBO Journal ·Xiao-Ping Xu, Isabelle Rouiller, Brian D. Slaughter, Coumaran Égile, Eldar Kim, Jay R. Unruh, Xiaoxue Fan, Thomas D. Pollard, Rong Li, Dorit Hanein, Niels Volkmann	60
11	Mechanism of Filament Nucleation and Branch Stability Revealed by the Structure of the Arp2/3 Complex at Actin Branch Junctions 2005 ·PLoS Biology ·Coumaran Égile, Isabelle Rouiller, (unknown), Niels Volkmann, Rong Li, Dorit Hanein	74
12	Activation of Arp2/3 complex-dependent actin polymerization by plant proteins distantly related to Scar/WAVE 2004 ·Proceedings of the National Academy of Sciences ·Mary J. Frank, Coumaran Égile, Julia Dyachok, Stevan Djakovic, (unknown), Rong Li, Laurie G. Smith	60
13	Formin Is a Processive Motor that Requires Profilin to Accelerate Actin Assembly and Associated ATP Hydrolysis 2004 ·Cell ·Stéphane Romero, Christophe Le Clainche, Dominique Didry, Coumaran Égile, Dominique Pantaloni, Marie-France Carlier	437
14	ARPC1/Arc40 Mediates the Interaction of the Actin-related Protein 2 and 3 Complex with Wiskott-Aldrich Syndrome Protein Family Activators 2004 ·Journal of Biological Chemistry ·Feng Pan, Coumaran Égile, (unknown), Rong Li	43
15	The RickA protein of Rickettsia conorii activates the Arp2/3 complex 2004 ·Nature ·Edith Gouin, Coumaran Égile, Pierre Dehoux, Véronique Villiers, Josephine C. Adams, Frank B. Gertler, Rong Li, Pascale Cossart	199
16	Structure of Arp2/3 Complex in Its Activated State and in Actin Filament Branch Junctions 2001 ·Science ·Niels Volkmann, Kurt J. Amann, Svetla Stoilova‐McPhie, Coumaran Égile, Dirk Winter, Larnele Hazelwood, John E. Heuser, Rong Li, Thomas D. Pollard, Dorit Hanein	189
17	Diversion of cytoskeletal processes by during invasion of epithelial cells 2000 ·Microbes and Infection ·Raphaëlle Bourdet‐Sicard, Coumaran Égile, Philippe J. Sansonetti, Guy Tran Van Nhieu	18
18	Rupture of the Intestinal Epithelial Barrier and Mucosal Invasion by Shigella flexneri 1999 ·Clinical Infectious Diseases ·Philippe Sansonetti, Guy Tran Van Nhieu, Coumaran Égile	71
19	Molecular bases of epithelial cell invasion by Shigella flexneri 1998 ·Antonie van Leeuwenhoek ·Philippe J. Sansonetti, Coumaran Égile	35
20	V gene usage by seven hybrids derived from CD5+ B-cell chronic lymphocytic leukemia and displaying autoantibody activity 1993 ·Blood ·Otto Pritsch, Christian Magnac, Gérard Dumas, Coumaran Égile, G Dighiero	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact